Welcome to our dedicated page for NewcelX news (Ticker: NCEL), a resource for investors and traders seeking the latest updates and insights on NewcelX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NewcelX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NewcelX's position in the market.
NewcelX (Nasdaq: NCEL) announced publication in China of an international patent application covering a new class of DOXA quinazoline, benzothiazine, and benzoxazine derivatives for neurological diseases (China publication CN 120981232 A, published November 18, 2025).
The portfolio expansion builds on a Europe priority filing (priority Dec 30, 2022) and a PCT filing (Dec 29, 2023), and the company says the DOXA family targets sleep‑wake regulation, neuroinflammation, oxidative stress, and neuronal resilience with potential applications across narcolepsy, ALS, neurodegeneration, and metabolic disease.
The publication supports NewcelX's small‑molecule IP footprint in Asia, mentions potential Hong Kong registration, and links DOXA mechanisms to the company's stem‑cell IsletRx work for insulin‑dependent diabetes.
NewcelX (Nasdaq: NCEL) announced on November 17, 2025 the appointment of Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board.
Prof. Shefner is Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute and is an ALS and neuromuscular disorder specialist with more than 200 peer-reviewed papers and co‑founder status of the Northeast ALS Clinical Trials Consortium (NEALS).
He will advise on NewcelX's ALS programs, including clinical development of AstroRx, and support integration of neuromuscular and neurodegenerative expertise into the company's cell‑therapy and neuroscience platform.
NewcelX (NASDAQ: NCEL) announced on November 6, 2025 that Professor Tamir Ben-Hur, MD, PhD, will join its Scientific Advisory Board.
Prof. Ben-Hur is a professor of neurology at Hadassah and Hebrew University, described as an expert in neuroimmunology and stem-cell regenerative medicine. Management said his appointment brings clinical expertise to NewcelX's programs targeting ALS and diabetes. The company framed his commitment as an endorsement of the Merger that unites Kadimastem's stem-cell platforms with NLS Pharmaceutic's CNS therapeutics capabilities.
NewcelX (Nasdaq: NCEL) issued a letter outlining a unified strategy combining cell therapies and neuroscience programs and setting multiple near-term clinical and corporate milestones over the next 12 months.
Key items include a planned U.S. Phase 2a study of AstroRx for ALS, preparation for a U.S. Phase 1 trial of IsletRx (iTOL-102), DOXA program progression toward lead selection, and platform expansion into indications such as MS and glaucoma. The merger that formed NewcelX raised approximately $9 million and the company cites a $25 million equity line of credit, with pro forma shareholders' equity of about $20 million as of June 30, 2025.
NewcelX (Nasdaq: NCEL) announced on November 3, 2025 that it has posted an investor presentation on its website. The company is a Swiss clinical-stage biopharmaceutical developer of cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, combining regenerative medicine and neuroscience expertise within a unified platform.
The investor presentation slides are available via the Corporate Presentation page in the Investor Relations & Media section at https://newcelx.com/investors-media/investors/corporate-presentation/.
FAQ
What is the current stock price of NewcelX (NCEL)?
What is the market cap of NewcelX (NCEL)?
